Annovis Bio Inc. (NYSE: ANVS), a late-stage clinical drug platform company focused on neurodegenerative diseases, has reported significant advancements in its Phase 3 trial for early Alzheimer’s disease and shared its second-quarter 2025 financial results. The trial, identified as NCT06709014, has now secured 76 U.S. sites, with 46 actively enrolling patients, 38 patients dosed, and nearly 200 in screening. The enrollment process is on track, maintaining an expected 50% screen failure rate.
Recent achievements by Annovis Bio include the presentation of four scientific posters at AAIC 2025, the appointment of a director of biostatistics, and the hosting of a trial update webcast. Additionally, the company has strengthened its intellectual property portfolio by securing global coverage for crystal buntanetap, a key component in its neurodegenerative disease treatment pipeline.
Financially, Annovis Bio has shown improvement, with cash and equivalents rising to $17.1 million as of June 30, 2025, up from $10.6 million at the end of 2024. The company reported a reduction in quarterly R&D expenses to $5.2 million from $5.8 million in the previous year, while G&A expenses decreased to $1.1 million from $2.0 million. This financial discipline contributed to a narrowed net loss per share of $0.32, down from $0.44.
The progress in the Phase 3 Alzheimer’s trial and the improved financial health of Annovis Bio are critical for the neurodegenerative disease treatment landscape. With Alzheimer’s disease affecting millions worldwide, advancements in treatment options are eagerly anticipated by patients, caregivers, and the medical community. The company’s efforts in expanding its clinical trial sites and enhancing its IP portfolio underscore its commitment to addressing unmet medical needs in neurodegenerative diseases.
For more detailed information on Annovis Bio’s recent developments and financial results, visit https://ibn.fm/iO1TH.
